Drug Profile
Cannabidiol nanotherapeutic - Cardiol Therapeutics
Alternative Names: CTX01Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Cardiol Therapeutics
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 antagonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Heart-failure in Canada (SC)
- 13 Jun 2018 Chemical structure information added
- 05 Jun 2018 Cardiol Therapeutics plans a phase I trials for Heart failure in the second half of 2018 (Cardiol Therapeutics pipeline, June 2018)